sofosbuvir and ledipasvir (n=125) vs. standard of care (n=125)
randomized controlled trial
Sofosbuvir/Ledipasvir
Sofosbuvir plus Ledipasvir once daily for 15 days.
Oseltamivir, Hydroxychloroquine, and Azithromycin.
Oseltamivir 150 mg q 12 hours for 10 days,HCQ 400 q 12 hours for one day followed by 200mg q 12 hours for nine days, and Azithromycin 500mg one time, followed by 250mg once daily for 6 days.
Additional medications were given, including third-generation cephalosporin Ceftriaxone 2 gm/24 hours for seven days, methylprednisolone 1 mg/kg/day for seven days, and prophylactic lowmolecular weight heparin (enoxaparin) 40 mg/24 hours was given throughout the hospitalizationperiod.
COVID 19 hospitalized
Moderate cases criteria: fever (measured temperature of at least 38 °C), respiratory symptoms (cough, shortness of breath), and imaging-confirmed pneumonia. Inclusion criteria also included age more than 18 and less than 75 years old.
Single-blind.
Single center, Egypt.
Nourian A, 2020 IRCT20100228003449
sofosbuvir and ledipasvir (n=45) vs. standard of care (n=45)
randomized controlled trial
Sofosbuvir/ledipasvir
SOF/LDP 400/90 mg daily for 10 days plus standard of care.
Standard of care
Standard of care alone.
In addition to the supportive care modalities, the standard of care according to the hospital protocol included hydroxychloroquine (HCQ 400 mg BD at first day then 200 mg BD for 7 days) plus atazanavir/ritonavir 300/100 mg daily for 7 days. Standard of care in both groups.
COVID-19 mild to moderate
Adult patients (≥18 years old) with highly suspected (according to the clinical signs/symptoms andimaging findings) or confirmed (a positive PCR of pharyngeal or nasopharyngeal samples) COVID-19 who were admitted to medical wards of the hospital, were included.
Clinical response was defined as one order decline in disease category in the five category ordinal scale. The categories are: death (5), mechanical ventilation (4), non-invasive ventilation (3), oxygen mask or nasal cannula (2), discharge(1).
